Previously, PP2 analogue was used to block the expression of IL-8 and VEGF, by blocking the Src kinase activation in tumour cells with high Src activity which was measured by the status of Src-phosphorylation at Y419 [42]. The gene discussed is VEGFA; the disease is neoplasm.